Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.

Curtis KK, Hartney JT, Jewell RC, Park JW, Lebowitz PF, Griffin PP, Borad MJ, Fitch TR, Northfelt DW.

J Clin Pharmacol. 2010 Mar;50(3):268-75. doi: 10.1177/0091270009343699. Epub 2009 Oct 6.

PMID:
19808951
2.

Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.

Herben VM, ten Bokkel Huinink WW, Schot ME, Hudson I, Beijnen JH.

Anticancer Drugs. 1998 Jun;9(5):411-8.

PMID:
9660538
3.

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A.

Clin Cancer Res. 1997 Aug;3(8):1245-52.

4.

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.

Chabot GG, Armand JP, Terret C, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J, Bonnay M.

J Clin Oncol. 1996 Jul;14(7):2020-30.

PMID:
8683232
5.

A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.

Kakolyris S, Kouroussis C, Souglakos J, Mavroudis D, Agelaki S, Kalbakis K, Androulakis N, Vardakis N, Vamvakas L, Georgoulias V.

Oncology. 2001;61(4):265-70.

PMID:
11721172
6.

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.

Clin Cancer Res. 1998 May;4(5):1153-8.

7.

Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.

Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ.

J Clin Oncol. 1998 Oct;16(10):3302-9.

PMID:
9779705
8.

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.

Gerrits CJ, Burris H, Schellens JH, Planting AS, van den Burg ME, Rodriguez GI, van Beurden V, Loos WJ, Hudson I, Fields S, Verweij J, von Hoff DD.

Eur J Cancer. 1998 Jun;34(7):1030-5.

PMID:
9849451
9.

A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)

Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Von Hoff DD, Verweij J.

Clin Cancer Res. 1999 Jan;5(1):69-75.

10.

No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.

Zackrisson AL, Malmström H, Peterson C.

Eur J Clin Pharmacol. 2002 May;58(2):103-8. Epub 2002 Apr 5.

PMID:
12012141
11.

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.

Clin Cancer Res. 2003 Sep 15;9(11):4092-100.

12.

Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.

Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DW, Steinherz PG, Whitlock JA, Holcenberg JS.

Clin Cancer Res. 1999 Dec;5(12):3956-62.

13.

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

Creemers GJ, Gerrits CJ, Eckardt JR, Schellens JH, Burris HA, Planting AS, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD.

J Clin Oncol. 1997 Mar;15(3):1087-93.

PMID:
9060549
14.

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M.

Ann Oncol. 1995 Feb;6(2):133-40.

PMID:
7786821
15.

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, O'Dwyer PJ.

Cancer Res. 1994 Mar 1;54(5):1220-6.

16.

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

Rose PG, Gordon NH, Fusco N, Fluellen L, Rodriguez M, Ingalls ST, Hoppel CL.

Gynecol Oncol. 2000 Aug;78(2):228-34.

PMID:
10926808
17.

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.

Wall JG, Burris HA 3rd, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, et al.

Anticancer Drugs. 1992 Aug;3(4):337-45.

PMID:
1330081
18.

Phase II study of oral topotecan in advanced non-small cell lung cancer.

White SC, Cheeseman S, Thatcher N, Anderson H, Carrington B, Hearn S, Ross G, Ranson M.

Clin Cancer Res. 2000 Mar;6(3):868-73.

19.

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

Burris HA 3rd, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, Fields S, Smith L, Von Hoff DD.

Anticancer Drugs. 1994 Aug;5(4):394-402.

PMID:
7949242
20.

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, et al.

J Clin Oncol. 1994 Mar;12(3):553-9.

PMID:
8120553
Items per page

Supplemental Content

Write to the Help Desk